A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Zilovertamab vedotin(biological)

Enrollment

1046 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2032

Study locations (30)

• Banner MD Anderson Cancer Center ( Site 0165), Gilbert, Arizona, United States
• Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167), Phoenix, Arizona, United States
• The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona, United States
• Providence Medical Foundation-Oncology ( Site 0168), Fullerton, California, United States
• Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos, California, United States
• Cedars-Sinai Medical Center ( Site 0115), Los Angeles, California, United States
• Pacific Hematology Oncology Associates ( Site 0131), San Francisco, California, United States
• Lutheran Hospital - Cancer Centers of Colorado ( Site 0180), Golden, Colorado, United States
• Clermont Oncology Center ( Site 0182), Clermont, Florida, United States
• Bioresearch Partner ( Site 0157), Hialeah, Florida, United States
• Orlando Health Cancer Institute ( Site 0169), Ocoee, Florida, United States
• Mid Florida Hematology and Oncology Center ( Site 0172), Orange City, Florida, United States
• Cancer Care Specialists of Illinois ( Site 0152), O'Fallon, Illinois, United States
• Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne, Indiana, United States
• Cotton O'Neil Cancer Center ( Site 0108), Topeka, Kansas, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT06829771
  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing
• RECRUITINGPHASE2NCT06554600
  A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →